Before Invest
JOHNSON & JOHNSON logo

JOHNSON & JOHNSON

JNJ
Pharmaceutical Preparations
Last filing · Quarter 2 · Jun 28, 2026
Financial Statements Ratios
Export XLSX
Unlock 14 years
Statement
Period
Annual Quarterly
Order
Format
% Change
Rows
USD ($)
$ in Millions, shares in Millions		LTMDec 28, 2025Dec 29, 2024Dec 31, 2023Jan 1, 2023Jan 2, 2022Jan 3, 2021Dec 29, 2019Dec 30, 2018Dec 31, 2017Jan 1, 2017Jan 3, 2016Dec 28, 2014Dec 29, 2013Dec 30, 2012Jan 1, 2012Jan 2, 2011Jan 3, 2010
Sales to customers
$ 97,929
$ 94,193
$ 88,821
$ 85,159
Cost of products sold
31,428
30,256
27,471
26,553
Gross profit
66,501
63,937
61,350
58,606
Selling, marketing and administrative expenses
25,141
23,676
22,869
21,512
Research and development expense
15,104
14,665
17,232
15,085
In-process research and development impairments
117
81
211
313
Interest income
912
1,056
1,332
1,261
Interest expense, net of portion capitalized
(1,012)
(971)
(755)
(772)
Other (income) expense, net
(630)
7,209
(4,694)
(6,634)
Restructuring
213
228
234
489
Earnings before provision for taxes on income
25,196
32,581
16,687
15,062
Effective Rate
4,159
5,777
2,621
1,736
Net earnings from continuing operations
26,804
26,804
14,066
13,326
Net earnings from discontinued operations
0
0
0
21,827
Net earnings
-
-
-
-
Add: Net loss attributable to noncontrolling interest
-
-
-
-
Net earnings
$ 21,037
$ 26,804
$ 14,066
$ 35,153
Net earnings per share
                  
Basic net earnings per share from continuing operations (in dollars per share)
$ 11.13
$ 11.13
$ 5.84
$ 5.26
Basic net earnings per share from discontinued operations (in dollars per share)
0
0
0
8.62
Basic (in dollars per share)
8.73
11.13
5.84
13.88
Diluted net earnings per share from continuing operations (in dollars per share)
11.03
11.03
5.79
5.2
Diluted net earnings per share from discontinuing operations (in dollars per share)
0
0
0
8.52
Diluted (in dollars per share)
8.62
11.03
5.79
13.72
Cash dividends per share (in dollars per share)
-
-
-
-
Average shares outstanding
                  
Basic (in shares)
2,408.1
2,407.4
2,407.3
2,533.5
Diluted (in shares)
2,443.9
2,429.4
2,429.4
2,560.4